期刊文献+

依帕司他共晶的制备、表征及性质研究

Preparation,Characterization and Property Research of Epalrestat Co-crystal
原文传递
导出
摘要 目的 制备依帕司他药物共晶,提高依帕司他水溶性。方法 以依帕司他为原料,4,4’-联吡啶为共晶前驱体,采用溶剂挥发法,制备得到依帕司他共晶。应用1H-NMR分析、X射线单晶衍射法、粉末X射线衍射法、差示扫描量热法、热重法等对制备得到的共晶进行表征。对共晶溶解性及引湿性进行了研究。结果 相较依帕司他原料药,共晶在水中的溶解度提高近40倍。结论 依帕司他共晶水溶性提升显著。 OBJECTIVE To prepare the eutectic of epalrestat and improve its water solubility.METHODS Using epalrestat as starting material and 4,4'-bipyridine as eutectic precursor,the epalrestat co-crystal was obtained by solvent volatilization.The structure of prepared co-crystal was characterized by 1H-NMR,X-ray single-crystal diffraction,power X-ray diffraction,differential scanning calorimetry and thermal gravimetric analysis respectively.The solubility and hygroscopicity of the co-crystal were also studied.RESULTS The solubility of epalrestat co-crystal in water was increased to nearly 40 times as compared with epalrestat raw materials.CONCLUSION The solubility of epalrestat co-crystal increased significantly.
作者 吴丽莎 孙慧慧 李银塔 元泉 王韶华 颜世强 WU Lisha;SUN Huihui;LI Yinta;YUAN Quan;WANG Shaohua;YAN Shiqiang(Weihai Ocean Vocational College,Weihai 264300,China;Shandong Dyne Marine Biopharmaceutical Co.Ltd.,Weihai 264300,China;Rongcheng Technology Transfer Service Center,Weihai 264300,China)
出处 《中国现代应用药学》 北大核心 2025年第13期2258-2262,共5页 Chinese Journal of Modern Applied Pharmacy
基金 山东省自然科学基金重点项目(ZR2020KH002)。
关键词 依帕司他 4 4’-联吡啶 共晶制备 表征 性质 epalrestat 4,4'-bipyridine co-crystal preparation characterization properties
  • 相关文献

参考文献8

二级参考文献32

  • 1黄碧瑶,宋金春,李香玉,冯育苗,姚青,高春生,何文,杨美燕.特考韦瑞固体分散体的制备与表征[J].军事医学,2019,43(11):865-870. 被引量:1
  • 2李笃信,薄改梅,卜新华.症状消除性抗糖尿病药依帕司他的合成[J].山西大学学报(自然科学版),1995,18(4):413-416. 被引量:3
  • 3于书海,杨凤岭,朱强,何文.依帕司他的合成[J].中国医药工业杂志,1996,27(1):5-6. 被引量:7
  • 4肖大凯,覃燕梅,莫丽儿,梁念慈.木犀草素对卵巢癌细胞株转移能力的影响[J].中国病理生理杂志,2006,22(6):1199-1202. 被引量:33
  • 5张毅,王旭光.木犀草素的体外抗炎机制研究[J].广州中医药大学学报,2007,24(3):231-234. 被引量:41
  • 6Clarke H D, Hickey M B, Moulton B, et al. Crystal engineering of isostructural quaternary multicomponent crystal forms of olanza- pine[J]. Cryst Growth Des, 2012, 12(8): 4194-4201.
  • 7Sowa M, lepokura K, Matczak-Jon E. Cocrystals of fisetin, luteolin and genistein with pyridinecarboxamide coformers: crystal structures, analysis of intermolecular interactions, spectral and thermal characterization[J]. CrystEngComm. 2013, 15(38): 7696.
  • 8Smith A J, Kavuru P, Wojtas L, et al. Cocrystals of quercetin with improved solubility and oral bioavailability[J]. Mol Pharmaceut. 2011, 8(5): 1867-1876.
  • 9Sowa M, lepokura K, Matczak-Jon E. A 1:1 pharmaceutical cocrystal of myricetin in combination with uncommon piracetam conformer: X-ray single crystal analysis and mechanochemical synthesis[J]. J Mol Struct, 2014, 1058:114-121.
  • 10苏红敏,张婷,罗亚楠,等.两种姜黄素有机药物共晶及其制备方法[P].中国,CNl02702092A.2012-10-03.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部